ArticleBMC pediatrics2026
Primary gastric mixed germ cell tumor in an infant: the pivotal role of dynamic alpha-fetoprotein surveillance in unmasking occult malignancy.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This paper reports a case of an extremely rare primary mixed germ cell tumor (MGCT) of the stomach in an infant. The patient, an 8-month-old male infant, presented with “black stool for three days.” Abdominal computed tomography (CT) suggested an abdominal space-occupying lesion, and gastroscopy revealed a huge cauliflower-like protrusion on the lesser curvature of the gastric body. The patient first underwent exploratory laparotomy for biopsy and adhesiolysis, followed by open resection of the abdominal mass with gastric wall repair, pyloroplasty, and abdominal drainage. Postoperative pathology suggested an immature teratoma (Grade I). After the initial surgery, although the pathological diagnosis was immature teratoma, serial AFP monitoring revealed persistently elevated levels that further increased significantly (from 465.8 ng/mL to over 1000 ng/mL within one week). Concurrent follow-up CT suggested a space-occupying lesion in the original tumor bed. The second laparotomy was performed for residual lesion in the original tumor bed combined with adhesiolysis and abdominal drainage, with the intent of achieving radical resection. Pathology confirmed MGCT (95% immature teratoma and 5% yolk sac tumor). The patient then received four cycles of alternating Vincristine + Cyclophosphamide + Cisplatin/Isocyclophosphamide + Etoposide + Vincristine (VCP/IEV) chemotherapy, after which AFP normalized. As of the last follow-up (August 2025), the patient has been disease-free for over 48 months and is in good general condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.